BREAKING NEWS: UnitedHealth Group (NYSE: UNH) closes LHC Group Inc. (Nasdaq: LHCG) transaction. More information below.
REGULAR UPDATE:
After a rough 2022, publicly traded post-acute providers are hoping to turn to a better page in the new year.
Almost all post-acute providers face significant staffing headwinds. It’s a near-universal problem. Home health providers, specifically, are dealing with those headwinds along with a dramatic shift in the way they’re paid.
Because Medicare Advantage (MA) plans are a much larger part of the equation than they used to be, providers are having to adjust.
“Transitioning the business to adjust to a new payer mix is certainly an uphill battle,” says Stoneridge Partners Managing Partner Joe Lynch. “It will be interesting to see which companies are able to seamlessly make the transition.”
The Stoneridge Home Health Index (HHI) increased 4% over the last month, while the Post-Acute Index (PAI) decreased by 4.5%.
Home Health Index
Though the HHI was up 4% month over month, that number was artificially dragged down by news about a possible Federal Trade Commission (FTC) challenge to UnitedHealth Group’s (NYSE: UNH) deal for LHC Group Inc. (Nasdaq: LHCG).
The FTC, however, did not make that challenge to the $5.4 Billion deal, which has now closed. LHC Group is no longer a tradable stock and was delisted effective Feb. 22, 2023.
Meanwhile, Amedisys Inc. (Nasdaq: AMED) had a terrific January, climbing 15.7%. It also beat Street expectations for the fourth quarter after Paul Kusserow returned to the CEO role.
The company recently divested its personal care division to the Massachusetts-based HouseWorks, and also announced a risk-based, in-home palliative care deal with BlueCross BlueShield of Tennessee.
Amedisys is positioning itself as a value driver for managed care, and is taking a hard stance on how it will contract with those health plans. It’s making deals with the ones that recognize its value, and promising to not work with those that do not recognize that value in contracts.
“I think home health is going to have more leverage than it thinks it has right now,” Kusserow told Home Health Care News. “And I think that’s going to be to Amedisys’ advantage, as well as the industry’s advantage.”
Post-Acute Care Index
After a rough December that saw its stock price dive by nearly 10%, Addus (Nasdaq: ADUS) turned things around in January. The company’s stock rose 8% month over month.
The biggest gainer in the greater post-acute space in the month, however, was the Pennant Group (Nasdaq: PNTG), which rose more than 17%.
The company is theoretically more insulated from looming home health rate cuts than others due to its senior living portfolio, but it has said that it would like to expand its home health reach.
In essence, Pennant is still bullish on the home health market, and in its ability to grow, both organically and through acquisitions.
“On the final rule, the negative behavioral adjustments represent a headwind for providers in our industry,” Pennant COO John Gochnour said during the company’s third-quarter earnings call. “Pennant’s home health and hospice segment began in, and has thrived through, periods of uncertainty and reimbursement cuts — much like today — thanks to the scalability of our operating model built on local leadership, our commitment to maintaining a strong and flexible balance sheet and our opportunistic approach to acquisitive growth.”
The S&P 500 rose 8% and outperformed the post-acute and home health indices in January, but some companies — including Amedisys and the Pennant Group — outperformed the market.
Quote of the Month
“CMS is committed to protecting people with Medicare and being a responsible steward of taxpayer dollars. By establishing our approach to RADV audits through this regulation, we are protecting access to Medicare both now and for future generations. We have considered significant stakeholder feedback and developed a balanced approach to ensure appropriate oversight of the Medicare Advantage program that aligns with our oversight of Traditional Medicare.” – Chiquita Brooks-LaSure, CMS Administrator
Read the Full Article Here: CMS Issues Final Rule for MA Risk Adjustment Audits
See It To Believe It!
The Stoneridge Partners Home Health Index (HH Index) is updated monthly and measures the performance of these two publicly traded home health companies, all listed on the NASDAQ:
- LHC Group (LHCG)
- Amedisys (AMED)
Here are the results of the stock prices for the past two years:
Company | 1/31/23 | 1 mos change | YTD change | 1/31/22 | 1/31/21 |
Amedisys | 96.66 | +15.71% | +15.71% | 135.04 | 289.07 |
LHC Group | 158.60 | -1.91% | -1.91% | 124.81 | 199.11 |
HH Index* | 127.63 | +4.09% | +4.09% | 129.93 | 244.09 |
S&P | 4076.60 | +5.13% | +5.13% | 4522.67 | 3731.17 |
Addus | 107.52 | +8.07% | +8.07% | 79.74 | 112.67 |
Although we track the performance of Addus, they are not included in our HH Index because very little of their revenue comes from Medicare.
Enterprise Value (EV)
EV (in M) | 2023 | 2022 | 2021 |
Amedisys | 3510 | 4490 | 10370 |
LHC Group | 5740 | 4050 | 6760 |
HH Index Total | 9250 | 8540 | 17130 |
Addus | 1820 | 1280 | 1950 |
Enterprise Value (EV), aka Selling Price, as Percent of Revenue
Company | 2023 | 2022 | 2021 |
Amedisys | 189% | 204% | 158% |
LHC Group | 251% | 187% | 249% |
HH Index Average* | 220% | 196% | 204% |
Addus | 178% | 153% | 196% |
The Stoneridge Partners Post-Acute Care Index is updated monthly and measures the performance of these six publicly traded post-acute care companies, all listed on the NASDAQ:
- LHC Group (LHCG)
- Amedisys (AMED)
- Addus (ADUS)
- The Pennant Group, Inc. (PNTG)
- Encompass Health (EHC)
- Brookdale Senior Living Inc. (BKD)
This graph displays Post-Acute Care Index performance starting late 2019.
The above calculations are based on selling price being defined as Enterprise Value (EV), with data provided by Capital IQ. Enterprise value is defined as market cap plus debt, minority interest and preferred shares, minus total cash and cash equivalents. EBITDA is calculated using methodology which may differ from that used by a company for its reporting. (Home Health Index February 2023 | Stoneridge Partners)
Recent Transactions From Around The Country
- The Brentwood, Tennessee-based health care system Lifepoint Health has acquired Cornerstone Behavioral Health El Dorado
- The electronic medical record (EMR) company Careficient Inc., has acquired Net Health’s home health, hospice, home care and palliative business, as well as its revenue cycle monitoring (RCM) products
- Quipt Home Medical Corp.’s acquired Great Elm Healthcare, expanding its footprint to 26 U.S. states
- Open Systems Healthcare, which provides in-home care in the Lehigh Valley and Reading area, has sold some of its operations to a larger rival.
View Stoneridge closed transactions on our website
Exclusively Listed For Sale By Stoneridge Partners.
Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.
Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.
Behavioral health specializing in PHP and IOP to high functioning patients. $4.6M in revenue with $1.3M EBITDA. In-network payor mix. Three locations. 20+ year market...
Behavioral Health/Suboxone Clinic. $900k in revenue. 21 years in business with stellar reputation. Single office, great opportunities for expansion. All cash paying patient base.
I/DD residential services. $11M in revenue. Highly profitable agency with long-standing reputation. Community Residential Services (CRS) 4-bed model & Integrated Community Supports (ICS) apartment settings.
Hospice. 65+ ADC. Expertly run with administrative tram willing to stay involved. No CAP or regulatory issues.
Well established home health agency. $4M in revenue. Fully staffed. Profitable. Good history of compliance.
Home Health CON in Montgomery County. Profitable agency generating over $1.3M in revenue. 95%+ Medicare. Built in marketing relationship and growth potential.
Skilled Home Health & Private Duty. $4.4 million in revenue. 22% census increase over last year. Established over 23 years.
Medicare/Medicaid Home Health agency. $8 million in revenue. Long history in the community.
86 patient hospice located Northeast of Houston, TX. $4M+ in revenue with 20% + adjusted EBITDA. Full staff in place. Excellent record of compliance.
Medicare-certified home health agency. District 9. $1.8M in revenue. Accredited.
Medicare-certified home health agency. District 7. Census of approximately 30 patients. Accredited.
Hospice. 150 ADC. Strong growth. Expertly run with administrative team willing to stay involved. No CAP or regulatory issues.
Established hospice organization on HCHB. 2 locations in greater Los Angeles/Southland area. Leadership team in place.
Mental Health Treatment Center. $1.1M in revenue. Long-established, profitable practice. Full spectrum of medical treatment and therapy services.
Medical Staffing Agency. $4.6M in revenue. Established over 25 years. Excellent rapport with regional hospital network.
Hospice agency. 6 counties in northern California. Moratorium in place. Minimal census. Accredited.
Medicare home health agency. Health system relationship. Rare KY CON opportunity, multiple counties
Large, established franchise territory. $2.5 million revenue. Two offices with strong leadership teams in place.
Home health with $8+M in revenue. Medicare/Medicaid-certified. 90+% traditional Medicare/episodic. Services central Texas and licensed for entire state. Strong management team in place.
Skilled home health agency. JCAHO accredited, zero deficiencies. Excellent reputation and referral relationships. $400k in revenue, impressive growth potential.
Medicare-certified home health agency. Houston-area. Minimal census.
Medicare-certified home health agency. $1M+ in revenue. Long-established agency with excellent community rapport.
In-home DME manufacturer. Patented mobility system. $7.7M+ in revenue. GSA/VA contract. Strong industry supplier partnerships.
$1M in revenue. Small Medicare home health agency. Region 5.
Medicare-certified home health agency. District 3. Approximately $700k in revenue. Accredited.
Medicare-certified home health agency. District 5. Minimal census. Accredited.
$19.5M large home care franchisee. 89% Medicaid. Well-established company operating more than 20 years. Phenomenal year-over-year revenue growth.
Well-established and profitable franchisee. Revenue of $4.9M. Medicaid and private pay.
4-star home health agency. $2.5 million revenue. Experienced management team. Strong financials with outstanding local reputation. Huge growth opportunities.
$3.3 million in revenue. Autism center providing ABA, OT, PT and ST. In-clinic and in-home services.
Non-skilled licensed home care organization. Approx. $2 million in annual revenue. Strong management team in place. Southern California.
Hospice with $3.5 million in annual revenue. Accredited. No cap or regulatory issues.
$2.5 million New Mexico home health agency. 87% Medicare. Long history in the community and existing staff in place.
Home Health / New Mexico / Popular
Home Health Index February 2023 | Stoneridge Partners
From Joe Lynch, Publisher of “Home Health Index.” Joe can be reached at [email protected] or (239) 561-0826, and toll-free at 800-218-3944. Previous editions of this monthly newsletter can be searched for at the bottom of the home page of the Home Health Index. Links to Google Finance: Amedisys | LHC Group